Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size.

Landh, E; M Moir, L; Bradbury, P; Traini, D; M Young, P; Ong, HX

Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size.

Landh, E M Moir, L Bradbury, P

Traini, D M Young, P Ong, HX

Permalink

Publisher:: FUTURE MEDICINE LTD
Publication Type:: Journal Article
Citation:: Nanomedicine (London, England), 2020, 15, (20), pp. 1927-1945
Issue Date:: 2020-08-21

Closed Access

	Filename	Description	Size
	17630132_5012760730005671.pdf	Published version	9 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Landh, E
dc.contributor.author	M Moir, L
dc.contributor.author	Bradbury, P https://orcid.org/0000-0001-6360-9591
dc.contributor.author	Traini, D
dc.contributor.author	M Young, P
dc.contributor.author	Ong, HX
dc.date.accessioned	2021-06-02T20:15:39Z
dc.date.available	2021-06-02T20:15:39Z
dc.date.issued	2020-08-21
dc.identifier.citation	Nanomedicine (London, England), 2020, 15, (20), pp. 1927-1945
dc.identifier.issn	1743-5889
dc.identifier.issn	1748-6963
dc.identifier.uri	http://hdl.handle.net/10453/149370
dc.description.abstract	<b>Background:</b> Lymphangioleiomyomatosis (LAM) is characterized by growth of smooth muscle-like cells in the lungs that spread to other organs via lymphatic vessels. Current oral rapamycin treatment is limited by low bioavailability of approximately 15%. <b>Aim:</b> The effect of inhaled rapamycin solid lipid nanoparticles (Rapa-SLNs) size on its penetration through the lymphatics. <b>Method:</b> Three Rapa-SLN formulations (200-1000 nm) were produced and assessed for particle characteristics and further for toxicity and performance <i>in vitro</i>. <b>Results:</b> Rapa-SLNs of 200 nm inhibited proliferation in TSC2-negative mouse embryonic fibroblast cells and penetrated the respiratory epithelium and lymphatic endothelium significantly faster compared with free rapamycin and larger Rapa-SLNs. <b>Conclusion:</b> Rapa-SLN approximately 200 nm allows efficient entry of rapamycin into the lymphatic system and is therefore a promising treatment for LAM patients.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	FUTURE MEDICINE LTD
dc.relation.ispartof	Nanomedicine (London, England)
dc.relation.isbasedon	10.2217/nnm-2020-0077
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0306 Physical Chemistry (incl. Structural), 1004 Medical Biotechnology, 1007 Nanotechnology
dc.subject.classification	Nanoscience & Nanotechnology
dc.title	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size.
dc.type	Journal Article
utslib.citation.volume	15
utslib.location.activity	England
utslib.for	0306 Physical Chemistry (incl. Structural)
utslib.for	1004 Medical Biotechnology
utslib.for	1007 Nanotechnology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	closed_access	*
dc.date.updated	2021-06-02T20:15:33Z
pubs.issue	20
pubs.publication-status	Published
pubs.volume	15
utslib.citation.issue	20

Abstract:

Background: Lymphangioleiomyomatosis (LAM) is characterized by growth of smooth muscle-like cells in the lungs that spread to other organs via lymphatic vessels. Current oral rapamycin treatment is limited by low bioavailability of approximately 15%. Aim: The effect of inhaled rapamycin solid lipid nanoparticles (Rapa-SLNs) size on its penetration through the lymphatics. Method: Three Rapa-SLN formulations (200-1000 nm) were produced and assessed for particle characteristics and further for toxicity and performance in vitro. Results: Rapa-SLNs of 200 nm inhibited proliferation in TSC2-negative mouse embryonic fibroblast cells and penetrated the respiratory epithelium and lymphatic endothelium significantly faster compared with free rapamycin and larger Rapa-SLNs. Conclusion: Rapa-SLN approximately 200 nm allows efficient entry of rapamycin into the lymphatic system and is therefore a promising treatment for LAM patients.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/149370